Study of satralizumab for NMOSD (real world evidence)
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study looks at how well satralizumab works in people with NMOSD (a rare disorder that affects the nerves in your eyes and spine). It is for people who have had recent flare-ups and test positive for a specific antibody (AQP4). You will receive satralizumab and be followed for at least one year to see if your disease stays under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older.
- You have NMOSD and a positive blood test for AQP4 antibodies.
- Your disability level (EDSS score) must be 8.5 or lower at the start of the study.
- You have had at least 1 NMOSD flare-up in the last year, or at least 2 in the last 2 years.
- You and your doctor plan to use satralizumab (a self-injected medication) for at least one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This trial tests a drug called sivelestat to see if it can help people who are currently having a relapse of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. The study aims to find out if the drug is safe and if it reduces symptoms during a relapse.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
Hear when a new Neuromyelitis Optica Spectrum Disorders (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.